Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,570.00+4.84%ETH$2,424.94+7.25%GOLD$4,090.40+0.43%OIL$87.98-0.16%
Smart Investors Daily
SID Premium
FL

NASDAQ · FLGT

Fulgent Genetics, Inc.

Healthcare · Medical - Diagnostics & Research

$19.37

Up+$0.31 (+1.60%)

Updated Nov 5, 2026, 12:40 AM

SID Score

5.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
830.31M
P/E ratio
-19.35
Dividend yield
0.00%
52-week range
$14.04 – $22.78
Volume
289.38K
Avg. volume
272.77K

Price performance · FLGT

FLGT price history

1M range · 0 trading sessions · Daily adjusted prices

FLGT does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest FLGT news

The latest Smart Investors Daily articles mentioning FLGT.

Stock researchCompany · Overview

FLGT research

Overview

Company profile and research snapshot.

Company profile

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$29.00
Implied upside
—
Analysts
—
FLGT recent ratings
DateFirmRatingTarget
Aug 4, 2026Piper SandlerNeutral—
May 5, 2026Piper SandlerNeutral—
Nov 11, 2025Piper SandlerNeutral—
Aug 5, 2025UBSBuy—
Aug 4, 2025Piper SandlerNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Global Pan-Ethnic Carrier Screening Programs Market Report 2026 | Capitalize on 14.1% CAGR as Illumina, Natera, Fulgent Genetics and LabCorp Scale AI and Multi-Gene Panels

Boost ROI via expanded gene panels, AI interpretation, tele-genetic counseling, routine prenatal integration and local reagent production to cut costs and widen access.Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Pan-Ethnic Carrier Screening Programs Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global pan-ethnic carrier screening programs market is experiencing rapid growth as healthcare systems expand access to genetic testing across diverse populations. The

Yahoo · Oct 15, 2026

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

EL MONTE, Calif., October 15, 2026--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer q

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By